MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerGlobeNewsWire · Oct 7, 2026
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)GlobeNewsWire · Oct 1, 2026
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open InterestBloomberg Markets and Finance · Sep 28, 2026
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and PortugalGlobeNewsWire · Sep 23, 2026
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung CancerGlobeNewsWire · Sep 22, 2026
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical TrialGlobeNewsWire · Sep 16, 2026MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.11 | -$0.13 | Miss |
| May 11, 2026 | -$0.18 | -$0.14 | Beat |
| Mar 23, 2026 | -$0.13 | -$0.08 | Beat |
| Nov 7, 2025 | -$0.19 | -$0.27 | Miss |
| Aug 11, 2025 | -$0.24 | -$0.18 | Beat |
| May 9, 2025 | -$0.18 | -$0.16 | Beat |